A plan taking place in almost 80 countries Subscription per five shares entitle the employee to one matching share[1] PARIS,…
Results showed Dupixent demonstrated a significant improvement in multiple asthma endpoints in two Phase 3 clinical trials in a broad…
PARIS, 25-Apr-2018 — /EuropaWire/ — Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June…
PARIS, 26-Feb-2018 — /EuropaWire/ — Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as…
Expands Sanofi’s presence in specialty care and strengthens leadership in rare diseases Adds leader in the growing hemophilia market and…
First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec PARIS,…
PARIS, 05-Dec-2017 — /EuropaWire/ — Following a planned interim analysis, the Independent Data Monitoring Committee (IDMC) for the phase III Cdiffense clinical trial…
LONDON, 01-Dec-2017 — /EuropaWire/ — On December 5-6, 2017, 200 high-level experts from government, academia, biopharmaceutical developers and patient organisations…
First study with a biologic to show benefit in severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil…
PARIS, 10-Aug-2017 — /EuropaWire/ — Sanofi announced today that it filed a patent infringement suit against Merck Sharp & Dohme Corp. (“Merck”)…
PARIS, 04-Jan-2017 — /EuropaWire/ — Sanofi announced today that Soliqua™ 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection)…
Both companies will become global leaders in two different sectors of the pharmaceutical market Paris (France) and Ingelheim (Germany), 03-Jan-2017…
PARIS, 03-Jan-2017 — /EuropaWire/ — Sanofi and its vaccines global business unit Sanofi Pasteur confirmed today the end of their…
PARIS, 04-Oct-2016 — /EuropaWire/ — Sanofi today announced the appointment of Alan Main as Executive Vice President Consumer HealthCare, effective…
PARIS, 31-Mar-2016 — /EuropaWire/ — Sanofi announced today the appointment of Dr. Yong-Jun Liu as Head of Research, Global R&D, effective…
Global introduction of the first Dengue Vaccine gains further momentum with this third approval in a row in an endemic…
LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone PARIS, 14-9-2015 — /EuropaWire/ — Sanofi announced today that the…
Genzyme Strengthens Endocrinology Portfolio with Acquisition of Rare Disease Therapy Caprelsa®(vandetanib) from AstraZeneca Paris, France, 30-7-2015 — /EuropaWire/ — Sanofi and…
Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration Companies agree to jointly advance PD-1 and other new immuno-oncology antibodies - Sanofi commits…
Investigational Enzyme Replacement Therapy to Treat Non-Neurological Manifestations which characterize Niemann-Pick Type B PARIS, 5-6-2015 — /EuropaWire/ — Sanofi and its…
PARIS, 9-3-2015 — /EuropaWire/ — Sanofi today announced the appointment of Robert Castaigne as Chairman of its Audit Committee. Mr. Castaigne succeeds…
Approval Establishes Genzyme’s MS Franchise in the U.S. with Two Approved Products; Follows Global Approvals PARIS, 17-11-2014 — /EuropaWire/ —…
Up to $200 Million Collaboration to Support Pioneering Science and New Treatments Paris and South San Francisco, CA, 18-9-2014 — /EuropaWire/…
In approximately 70 percent of patients, disability scores improved or remained stable for an additional two years beyond the two-year…
Only First-Line Oral Treatment for Adult Gaucher Disease Type 1 Paris, 22-8-2014 — /EuropaWire/ — Genzyme, a Sanofi company (EURONEXT: SAN…
First shipment marks a critical step in improving access to treatment worldwide Paris, France, and South San Francisco, United States, 19-8-2014…
Initial focus on insulin-device combinations and care management services Paris and Minneapolis, Minn., 16-6-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE:…
Both doses of investigational drug sarilumab met all three co-primary endpoints New data include major clinical response rates and ACR20…
Meta-analysis of three late-stage trials in people with type 2 diabetes shows decreases in risk of low blood sugar events…
Shan5™ is the first vaccine jointly developed by the Indian company and its parent company Sanofi Pasteur WHO’s decision allows for…
Appointment is a First for a Top 10 Biopharmaceutical Company Paris, France, 1-4-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY)…
Companies To Host Investor Conference Call on Alirocumab on March 31 at 9 a.m. EDT Paris, France and Tarrytown, NY,…
Paris, France, 31-1-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it filed a patent infringement suit against Eli…
Paris, France, 30-1-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that RobecoSAM, which measures the performance of companies in…
Paris, France, 21-11-2013 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the decision to halt all clinical trials and cancel…
Paris, France, 12-11-2013 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announces that it has successfully priced its offering of EUR 1…
Treats Seasonal and Year-round Nasal Allergy Symptoms in Adults and Children Paris, France, 06-8-2013 — /EuropaWire/ — Sanofi (EURONEXT: SAN and…
Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide Lyon, France, 06-8-2013 — /EuropaWire/ — Sanofi Pasteur,…